Gara Jalqabaatti › Sklerosis Baay’ee
Qorannoo klinikaalii Sklerosis Baay’ee Ameerikaa Keessatti hirmaatuu
Qorannoo 131 Sklerosis Baay’ee f bakka adda addaa Ameerikaa Keessatti hirmaatuu jiru.
Magaalota qorannoo baay'ee qaban
- New York City, NYQorannoo 17
- Chicago, ILQorannoo 15
- Boston, MAQorannoo 14
- Washington, DCQorannoo 13
- Cleveland, OHQorannoo 9
- San Francisco, CAQorannoo 8
- Birmingham, ALQorannoo 8
- St. Louis, MOQorannoo 8
- Kansas City, KSQorannoo 8
- Aurora, COQorannoo 7
- Columbus, OHQorannoo 7
- Baltimore, MDQorannoo 7
- Houston, TXQorannoo 6
- Seattle, WAQorannoo 6
- Milwaukee, WIQorannoo 6
- Farmington Hills, MIQorannoo 6
- Dallas, TXQorannoo 6
- Tampa, FLQorannoo 5
- San Diego, CAQorannoo 5
- Austin, TXQorannoo 5
- Atlanta, GAQorannoo 5
- Brockton, MAQorannoo 4
- Naples, FLQorannoo 4
- Knoxville, TNQorannoo 4
- Scottsdale, AZQorannoo 4
- Ann Arbor, MIQorannoo 4
- Miami, FLQorannoo 4
- Champaign, ILQorannoo 4
- New Haven, CTQorannoo 4
- Durham, NCQorannoo 4
- Orlando, FLQorannoo 4
- Kirkland, WAQorannoo 3
- Philadelphia, PAQorannoo 3
- Cincinnati, OHQorannoo 3
- Mountain View, CAQorannoo 3
- Rochester, MNQorannoo 3
- Newark, NJQorannoo 3
- Clifton, NJQorannoo 3
- Honolulu, HIQorannoo 3
- Sandy Springs, GAQorannoo 3
Naannoon
- AlabamaQorannoo 8
- ArizonaQorannoo 6
- CaliforniaQorannoo 24
- ColoradoQorannoo 11
- ConnecticutQorannoo 6
- Distaarikii KoloombiyaaQorannoo 4
- FloridaQorannoo 14
- GeorgiaQorannoo 7
- HawaiiQorannoo 3
- IllinoisQorannoo 19
- KansasQorannoo 9
- KentuckyQorannoo 3
- MarylandQorannoo 17
- MassachusettsQorannoo 18
- MichiganQorannoo 10
- MinnesotaQorannoo 4
- MissouriQorannoo 8
- NebraskaQorannoo 3
- New JerseyQorannoo 11
- New YorkQorannoo 19
- North CarolinaQorannoo 8
- OhioQorannoo 14
- OklahomaQorannoo 3
- PennsylvaniaQorannoo 7
- TennesseeQorannoo 6
- TexasQorannoo 17
- UtahQorannoo 3
- VirginiaQorannoo 3
- WashingtonQorannoo 10
- WisconsinQorannoo 7
Qorannoo yeroo dhihootti haaromfaman
Takkalaa qorannoo (Ingiliffa)
Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT02784210Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 05-Onk-2026 · NCT03816345A Study of the MIND Diet for Persons With Multiple Sclerosis
Namoota walitti qabaa jira
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT06992115Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
1 Month – 99 Years · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT00794352Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 02-Onk-2026 · NCT03109288A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 01-Onk-2026 · NCT06782490A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
Namoota walitti qabaa jiraSadarkaa 4
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 30-Ful-2026 · NCT07609719Vancomycin Study in Multiple Sclerosis (MS)
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 hanga 50 · Saalaa hunda · Haaromfame 28-Ful-2026 · NCT05539729A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 70 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07840326Understanding the Impact of Meal Timing on Neurological Health in Adults With Multiple Sclerosis
Namoota walitti qabaa jira
Umuriin 18 hanga 64 · Saalaa hunda · Haaromfame 25-Ful-2026 · NCT07475377A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 23-Ful-2026 · NCT06433752Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis
Namoota walitti qabaa jiraSadarkaa 1/2
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 21-Ful-2026 · NCT07477639A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
Namoota walitti qabaa jiraQorannoo ilaalaa
Umuriin 15 hanga 50 · Dubartoota · Haaromfame 21-Ful-2026 · NCT06433765Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis
Namoota walitti qabaa jira
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 17-Ful-2026 · NCT07606742Clinical Applications of Advanced Ophthalmic Imaging
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
Umuriin 18 hanga 99 · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT03135327Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 hanga 120 · Saalaa hunda · Haaromfame 16-Ful-2026 · NCT00001248Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
Namoota walitti qabaa jira
Umuriin 18 hanga 65 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT05958381RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Namoota walitti qabaa jiraSadarkaa 2
Umuriin 18 hanga 80 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07002034Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 18 hanga 60 · Saalaa hunda · Haaromfame 15-Ful-2026 · NCT07325292Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Namoota walitti qabaa jiraSadarkaa 3
Umuriin 10 hanga 17 · Saalaa hunda · Haaromfame 10-Ful-2026 · NCT06408259Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Namoota walitti qabaa jiraSadarkaa 1Hojjettoota fayyaa simatamoo
Umuriin 18 hanga 90 · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06999434A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Namoota walitti qabaa jiraSadarkaa 1
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 09-Ful-2026 · NCT06680037Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 2 hanga 120 · Saalaa hunda · Haaromfame 31-Hag-2026 · NCT01730131Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain
Namoota walitti qabaa jira
Umuriin 18 hanga 75 · Saalaa hunda · Haaromfame 28-Hag-2026 · NCT07132775Identifying and Characterizing Preclinical MS
Namoota walitti qabaa jiraQorannoo ilaalaaHojjettoota fayyaa simatamoo
Umuriin 18 fi ol · Saalaa hunda · Haaromfame 27-Hag-2026 · NCT05787795Kanneen ClinicalTrials.gov irraa argaman, daataa 06-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.